SCHEMBL25919340

SCHEMBL25919340

CCCCCCCCCOC(=O)CCCCCN(CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.43
PRKCA P17252 1/20 0.42
PRKCE Q02156 1/20 0.42
PRKCQ Q04759 1/20 0.42
PRKCD Q05655 1/20 0.42
DNM1 Q05193 1/20 0.41
DGKA P23743 1/20 0.41
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
THRA P10827 2/20 0.40
THRB P10828 2/20 0.40
TLR2 O60603 1/20 0.40
ENPP2 Q13822 1/20 0.38
LPAR1 Q92633 1/20 0.38
LPAR3 Q9UBY5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25419620 0.96 ALDH1A1 (0.46) ALDH1A1L3MBTL1LMNAPRKCAPRKCE
SCHEMBL25417070 0.96 ALDH1A1 (0.46) ALDH1A1L3MBTL1LMNAPRKCAPRKCE
SCHEMBL25418208 0.96 ALDH1A1 (0.46) ALDH1A1L3MBTL1LMNAPRKCAPRKCE
SCHEMBL17367570 0.94 GAA (0.47) ALDH1A1L3MBTL1LMNAGAAPRKCA
SCHEMBL22645901 0.93 ALDH1A1 (0.43) ALDH1A1L3MBTL1LMNAPRKCAPRKCE
SCHEMBL18641719 0.93 ALDH1A1 (0.43) ALDH1A1L3MBTL1LMNAPRKCAPRKCE
SCHEMBL30516547 0.92 ALDH1A1 (0.43) ALDH1A1L3MBTL1LMNAPRKCAPRKCE
SCHEMBL18665091 0.92 TLR2 (0.49) ALDH1A1L3MBTL1LMNAPRKCAPRKCE
SCHEMBL25192867 0.91 ALDH1A1 (0.42) ALDH1A1L3MBTL1LMNAPRKCAPRKCE
SCHEMBL25415609 0.91 ALDH1A1 (0.42) ALDH1A1L3MBTL1LMNAPRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233706-A1 In vivo targeting of CD4+-T cells for mRNA therapeutics THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2023-07-27 US disclosed
US-20230233706-A1 In vivo targeting of CD4+-T cells for mRNA therapeutics THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233706-A1 In vivo targeting of CD4+-T cells for mRNA therapeutics CD4, CD74, HAVCR2 ALDH1A1 4078/4885L3MBTL1 142/4885LMNA 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.